Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia

Authors:

Abstract
Schizophrenia is a life-long illness that typically requires maintenance antipsychotic treatment throughout an individual’s life.1 Older age1,2 is a risk factor for antipsychotic-induced adverse effects, including parkinsonism, tardive dyskinesia, falls, and metabolic syndrome.3,4 Clinical guidelines5 developed by expert consensus recommend the use of lower doses of antipsychotics in older patients with schizophrenia. However, empirical data on age-specific antipsychotic dosing are limited.6

This publication has 29 references indexed in Scilit: